三尖瓣反流介入治疗进展  

Progress of tricuspid regurgitation interventional treatment

作　　者：索田源 汪宇鹏[1] SUO Tian-yuan;WANG Yu-peng(Department of Cardiology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院心血管内科,北京100191

出　　处：《中国介入心脏病学杂志》2024年第10期588-595,共8页Chinese Journal of Interventional Cardiology

基　　金：科技部重点研发计划项目(2023YFC2414403)。

摘　　要：三尖瓣反流(TR)是一种常见的心脏瓣膜疾病。随年龄不断上升的发病率、疾病晚期的高死亡率,使得越来越多的人关注到三尖瓣与TR。对于重度TR患者,以利尿剂为核心的药物治疗效果不佳,而外科治疗又面临患者年龄偏大、手术死亡率高等问题,经导管三尖瓣介入技术(TTVI)在近年来取得了迅速发展。目前,得到应用的TR介入治疗设备可分为瓣膜修复和瓣膜置换两大类,这些设备均展现出安全性和有效性,并有初步的临床试验作为支持。本文介绍了TR治疗器械及其相关临床试验的进展。Tricuspid regurgitation(TR)is a common heart valve disease.The increasing morbidity with age and the high mortality in the later stage of TR make more and more people pay attention to tricuspid valve(TV)and TR.For patients with severe TR,medicine management with diuretic as the core is not effective enough,and surgical management is faced with the problem of old patients,high surgical mortality.Transcatheter tricuspid valve interventions(TTVI)has made rapid progress in recent years.Currently,devices for TR can be divided into 2 categories:valve repair and valve replace.Both of them have demonstrated safety and efficacy,and are supported by preliminary clinical trials.In this review,the progress of relevant devices for tricuspid valve regurgitation and their clinical trials are introduced.

关 键 词：三尖瓣反流 介入治疗 经导管三尖瓣修复 经导管三尖瓣置换 

分 类 号：R541[医药卫生—心血管疾病]